You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

CLINICAL TRIALS PROFILE FOR NAPROXEN SODIUM


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for naproxen sodium

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
OTC NCT00751400 ↗ Naproxen Sodium Extended-Release Actual Use Study Completed Pegus Research, Inc. Phase 3 2008-07-01 The purpose of this Study is to assess how subjects will use the investigational product in an uncontrolled, naturalistic environment.
OTC NCT00751400 ↗ Naproxen Sodium Extended-Release Actual Use Study Completed Bayer Phase 3 2008-07-01 The purpose of this Study is to assess how subjects will use the investigational product in an uncontrolled, naturalistic environment.
OTC NCT01365052 ↗ Safety Trial of Naproxen Sodium/ Diphenhydramine Completed Bayer Phase 3 2011-05-01 The purpose of this trial is to see how safe the combination of naproxen sodium 440 mg and diphenhydramine hydrochloride (DPH) 50 mg (the investigational product) is compared to placebo (capsules containing no drug) when taken for 10 days.
OTC NCT01383486 ↗ Self Selection Trial of Naproxen Sodium Completed Bayer Phase 3 2011-07-01 A pilot trial to demonstrate that consumers can appropriately select Aleve 24 Hour for their own use based on expected duration of pain greater than 12 hours.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for naproxen sodium

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00092729 ↗ An Investigational Drug Study in the Treatment of Primary Dysmenorrhea (0663-064) Completed Merck Sharp & Dohme Corp. Phase 3 2002-06-07 The purpose of this study is to evaluate the pain relieving effect and safety of an investigational drug in women with moderate to severe primary dysmenorrhea (painful menstruation).
NCT00114049 ↗ Dental Pain (Following Third Molar Tooth Extraction) Study Completed GlaxoSmithKline Phase 3 2004-12-01 The purpose of this study is to evaluate the effectiveness of GW406381 (a COX-2 inhibitor) in treating the signs and symptoms of dental pain following third molar tooth extraction.
NCT00240617 ↗ Study Of Treximet, Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks Completed GlaxoSmithKline Phase 3 2005-10-01 The purpose of this study is to determine the consistency of response for Treximet (formerly known as Trexima) when treating four acute migraine attacks at the mild pain phase and within 1 hour of onset of head pain.
NCT00240630 ↗ Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks Completed GlaxoSmithKline Phase 3 2005-10-01 The purpose of this study is to determine the consistency of response for Treximet (sumatriptan/naproxen sodium), formerly known as Trexima, when treating four acute migraine attacks at the mild pain phase and within 1 hour of onset of head pain.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for naproxen sodium

Condition Name

Condition Name for naproxen sodium
Intervention Trials
Migraine Disorders 16
Pain 14
Healthy 12
Migraine 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for naproxen sodium
Intervention Trials
Migraine Disorders 28
Toothache 8
Pain, Postoperative 8
Dysmenorrhea 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for naproxen sodium

Trials by Country

Trials by Country for naproxen sodium
Location Trials
United States 404
Canada 4
India 4
Turkey 3
Brazil 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for naproxen sodium
Location Trials
Utah 29
Texas 28
Florida 17
California 17
Missouri 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for naproxen sodium

Clinical Trial Phase

Clinical Trial Phase for naproxen sodium
Clinical Trial Phase Trials
Phase 4 26
Phase 3 30
Phase 2/Phase 3 3
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for naproxen sodium
Clinical Trial Phase Trials
Completed 83
Not yet recruiting 6
Recruiting 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for naproxen sodium

Sponsor Name

Sponsor Name for naproxen sodium
Sponsor Trials
Bayer 25
GlaxoSmithKline 23
Dr. Reddy's Laboratories Limited 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for naproxen sodium
Sponsor Trials
Industry 79
Other 56
NIH 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.